First Clinical Trial With Induced Pluripotent Stem Cells Grows Closer
        
            By Dennis Normile, 
                Science
             | 06. 26. 2013
        
                    
                                    
                    
                                                                                                                                    
                                                                            
                              
    
  
  
    
  
          
  
      
    
            A Japan Ministry of Health, Labour and Welfare panel has accepted a plan to carry out what would be the world's first clinical trials involving induced pluripotent stem (iPS) cells. The acceptance paves the way for an official green light from the ministry, which could come in early July.
Researchers at the RIKEN Center for Developmental Biology in Kobe plan to generate replacement retinal pigment epithelial cells from iPS cells generated from patients suffering age-related macular degeneration. The research has been under way for several years and was widely 
reported at conferences.
Approval for clinical trials was expected to be routine. However, the health ministry panel cited safety concerns in putting off a decision in late May. Japanese media reported that the panel met again today and accepted additional data submitted by RIKEN. Formal approval will be up to the ministry. RIKEN could start recruiting patients sometime this year.
 
 
  
 
    
    
  
   
                        
                                                                                
                 
                                                    
                            
                                  
    
  
  
      Related Articles
    
  
          
  
  
  
  
  
  
      
            
                  
  
      
    
    
                
                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                           By Emma Belmonte,  ChinaFile | 10.03.2025
                                                        
     
    
    
            
On the popular Chinese social media platform Xiaohongshu, also known as RedNote, an account called “Georgia Notes” (@格鲁吉亚小纸条) offers tips and advice to Chinese nationals planning a trip to the Republic of Georgia. In one post...
 
       
 
 
  
      
    
    
                
                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                           By Karin Hammarberg, Alex Polyakov, Catherine Mills, and Karinne Ludlow,  The Conversation | 10.03.2025
                                                        
     
    
    
            Reports of several cases of embryo and sperm mix-ups have put the Australian fertility industry in the spotlight for all the wrong reasons.
These bungles have raised serious questions about the industry’s current model of self-regulation, and demonstrate a lack...
 
       
 
 
  
      
    
    
                
                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                           By Jared Whitlock,  Endpoints News | 10.09.2025
                                                        
     
    
    
            When Nirnay Murthy learned about a treatment for his toddler son’s rare condition, relief quickly gave way to disappointment.
A one-time gene therapy called Zolgensma from the Swiss drugmaker Novartis can halt spinal muscular atrophy, a deadly condition that causes...
 
       
 
 
  
      
    
    
                
                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                           By Karin Hammarberg and Catherine Mills,  BioNews | 10.13.2025
                                                        
     
    
    
            
The Australian fertility industry has been rocked by several recent cases of embryo and sperm mix-ups. With a lack of transparency about what clinics do to prevent such errors recurring, trust and confidence in the industry and how it is...